The development of STING agonists for cancer has been beset by safety issues and discontinued programmes, but Daiichi Sankyo is hoping a new antibody-drug conjugate (ADC) could succeed where others ...
You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Sting is back on tour with his ongoing STING 3.0 run, a smaller-scale live setup that strips things ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results